Foundation for the National Institutes of Health

You can join the fight against amyotrophic lateral sclerosis (ALS).  ALS is a progressive, devastating neurological disease, but together, we can accelerate progress. In our latest paper, my colleagues Sri Ramulu Pullagura, PhD, Shubhangi Lal and I highlight how YOU can make an impact by joining the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS), a groundbreaking initiative, which unites the NIH, FDA, FNIH, academia, industry, NPOs and patient advocates. Here’s how you can engage: - Researchers & Institutions: Share your findings, join collaborative studies, and help uncover the biomarkers and targets that could change lives. - Industry Partners: Team up with AMP ALS to pool resources and expertise for developing more effective treatments and cures. - NPOs: Spread the word, recruit participants, team up with AMP ALS. - People with Lived Experience (PWLE) & Caregivers: Share your experiences to inform research. Join a clinical consortium shaping the future of ALS care through a natural history study of over 2,000 participants. - Funding Agencies & Philanthropists: Invest in hope—your support drives innovation and sustains this initiative. I want to thank Dan Doctoroff, Stephanie Melillo Fradette, and Amelie Gubitz, who are providing leadership as co-chairs of the initiative, and all our current partners. Together, we can make a difference. Together, we can make progress faster. Find your role in this mission and let’s accelerate progress. Foundation for the National Institutes of Health, #research #collaboration #Innovation #BridgeToBreakthrough, #Neuroscience #ClinicalResearch #TranslationalScience #ALS #FNIH https://lnkd.in/e9Ft9SmB

A recent thematic issue of the Journal of Clinical and Translational Science highlights insights from the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. Launched at the onset of the COVID-19 pandemic, ACTIV brought together experts from the NIH, the FNIH, and over 30 organizations to fast-track the development of treatments and other therapeutics for COVID-19. Over nearly five years, the program launched 11 master protocols, evaluating 37 therapeutic agents across diverse patient settings. The collection of articles, written and edited by several key members of the ACTIV team, underscores key strategies for addressing public health emergencies, including: 🤝 fostering strong public-private partnerships, 📢 engaging communities to ensure diverse trial participation, and 🏥 designing flexible, adaptive clinical trials. By sharing these lessons, we aim to equip future healthcare leaders and researchers with the tools to respond effectively to emerging global health challenges. Read the full issue: https://ow.ly/k0Fe50UuxKm

What better time than the holidays to express our gratitude for our partners in government, academia, life science organizations, and patient advocacy. It takes all of us — including leaders, researchers, scientists, patients, benefactors, philanthropists, and FNIH team members — to make a difference. Learn more about our mission to build bridges to breakthroughs in support of the NIH: https://fnih.org/ #FNIH #BridgestoBreakthroughs #TeamScience

The FNIH values our partnerships with amazing people like Parkinson’s advocate Dr. Soania Mathur, who shares her insights and lived experiences to support our Accelerating Medicines Partnership® for Parkinson’s Disease and Related Disorders. This program enables a precision medicine-driven approach to support earlier diagnosis and better treatments for people with these diseases. Read her inspiring story, recently featured in Brain & Life magazine: https://lnkd.in/gDDH4trf PD Avengers

Thank you to everyone who helped build bridges to breakthroughs on #GivingTuesday! Your support will accelerate medical research designed to bring life-changing solutions to those who need themit most. Just imagine a future where: 💖 Children will have the same access to life-saving medical devices as adults. 💖 Diagnosis will be faster, and treatments more effective, for those with Parkinson’s and ALS. 💖 Medical researchers will get the support they need to make breakthroughs for patients. This, and much more, is possible because of the support we receive from you and other donors. Thank you for helping to provide hope to millions! Learn more: https://lnkd.in/eHpjFNRa

HOPE — it’s embedded in everything we do — from supporting innovative research to funding exceptional scientists. When you make a gift to the FNIH on #GivingTuesday, it accelerates and amplifies medical breakthroughs that bring hope to millions. Imagine the future you could help create: 💖 Children will have the same access to life-saving medical devices as adults. 💖 Diagnosis will be faster, and treatments more effective, for those with Parkinson’s and ALS. 💖 Medical researchers will get the support they need to make breakthroughs for patients. These are just a few of the many ways your partnership will bring life-changing solutions to those who need it most. Make your gift today, and together, we will build a healthier, more hopeful future. https://lnkd.in/eHpjFNRa

The FNIH is supporting team research that has led to a better understanding of the underlying biology of Alzheimer’s disease and is now translating into innovative solutions for improving patient outcomes. FNIH partners Joel Braunstein, C2N Diagnostics, and Diane Stephenson and Klaus Romero, Critical Path Institute, reflected recently on both the outstanding progress in the field of Alzheimer’s disease and the challenges ahead. #AlzheimersAwarenessMonth

The hope of transforming the lives of patients drives Howard Y. Chang, MD, PhD, and Vijay G. Sankaran, MD, PhD, two researchers who were recognized during the FNIH Awards Ceremony. Watch as they discuss what drew them to science, how they build teams, and where they are heading with FNIH President and CEO Julie L. Gerberding, MD, MPH. https://lnkd.in/eANMRubm @howard-chang-3194a44 Stanford University Stanford University School of Medicine Dana-Farber Cancer Institute Boston Children's Hospital Harvard Medical School

A big thank-you from everyone at the FNIH to all our partners in public health. We appreciate all you do to strengthen our communities. #PHTYD! #FNIH #BridgestoBreakthroughs

Learn about exciting advancements in virology research at the Norman P. Salzman Memorial Awards and Symposium on Dec. 5 at the Lipsett Auditorium in the NIH Clinical Center. Featured scientists will include Post-Baccalaureate Awardee Walker Symonds-Orr. His research explored how Enterovirus A71 tolerates genetic changes like insertions and deletions, especially in the capsid region. He found that the virus has limited flexibility for such changes, which affects its evolution. He also developed tools to label and study viral proteins, helping to better understand their roles during infection. Register now: https://lnkd.in/dbFusfUU